UK government targets manufacturing as it eyes £41bn life science sector growth
In a new Life Sciences sector plan, the government outlined a six-point action plan to ensure the sector reaches its forecasted value increase of £41bn, representing a growth of 165% by 2035. The government is aiming to make the UK the leading life sciences economy in Europe, and third largest in the world behind only America and China.
While excelling at research and development (R&D), the report outlines difficulties with commercialisation and adoption. For example, despite being the first country to approve a CRISPR-based medicine, Vertex and CRISPR Therapeutics' Casgevy for sickle cell anaemia is primarily commercialised overseas.
In a bid to scale industry, the government has pledged £520m to improve life science manufacturing. Outlaid via the Life Sciences Innovative Manufacturing Fund (LSMIF), the investment will aim to expand the UK's manufacturing capabilities and supply chain security.
The initiative comes at a crucial time, as British pharmaceutical companies are significantly increasing their investments in the United States. GSK invested $800m in drug substance and drug product manufacturing facilities in the US in October 2024. AstraZeneca – which has a market cap of £162bn – is reportedly plotting a move of its public listing to the US stock exchange in what would be a major blow to the UK economy.
To facilitate the industry's expansion, the government will look to increase access to scale-up capital. There has been a cautious domestic investor base, leading to a lull in emerging companies with high economic outputs. The government will measure investment by the number of UK life science companies with a valuation of over £10bn, the number of companies on the FTSE 300, and the number of initial public offerings (IPOs) in the sector.
From a regulatory standpoint, the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute of Care and Excellence (NICE) will be supported to provide faster approvals and more efficient reimbursement.
Optimism and criticism for UK life sciences
MHRA's chief executive Lawrence Tallon welcomed the news, saying: 'It's great to see the MHRA is recognised as a pivotal partner in delivering the plan's vision - by supporting innovation, protecting public health, and making the UK a global destination for innovators to research, develop and launch cutting-edge medical products.'
David Stockdale, chief executive of the British Healthcare Trades Association (BHTA) highlighted the importance of reducing regulatory and financial barriers to accelerate faster delivery of innovative MedTech solutions to patients.
"We welcome today's announcement which rightly aims to make the UK a leading hub for investment and innovation in lifesaving MedTech, an essential step if we are to improve patient care and cut down waiting times. We particularly welcome the renewed commitments to the Life Sciences Innovative Manufacturing Fund and the NHS Innovator Passports. Our members are eager to deliver their innovative products and services to patients more quickly and efficiently, and we look forward to working with the Government to make this a reality.
Clinical trials are set to benefit from the plan, with a new 150 day or lower target for trial set up times. Finally, up to £600m will be put towards an artificial intelligence (AI)-ready health data platform, a strategy already launched in April 2025.
The BioIndustry Association (BIA) said: 'The life science sector plan is right to focus on getting substantially more public and private investment in early-stage companies, improved access to data, trials and skills to help companies grow, and more streamlined regulation and market access pathways to get innovative medicines to NHS patients.'
However, the Association of the British Pharmaceutical Industry (ABPI) commented that the plan falls short of investing in innovative medicines.
Richard Torbett, Chief Executive of the ABPI, said: [The UK life sciences sector] has been struggling to remain competitive and attractive to investment. The solutions proposed are necessary and important, but they are not enough to turn around the UK's decline.
'The UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications that are available in other countries.'
The life science sector plan comes hot on the heels of the 10-year health plan unveiled for the NHS earlier this month, which placed emphasis on technology and digitalisation.
"UK government targets manufacturing as it eyes £41bn life science sector growth" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Insider
6 minutes ago
- Business Insider
Western arms makers can now live-test their prototype weapons on the battlefield against Russia's forces
Ukraine is inviting foreign arms manufacturers to send weapons prototypes for its troops to test in battle against Russian forces. Its defense innovation unit, Brave1, on Thursday launched "Test in Ukraine," a program that it said would trial the new tech in combat and produce a detailed report for the defense contractor. "This is an opportunity to gain experience that cannot be simulated in laboratories," said Mykhailo Fedorov, Ukraine's minister for digital transformation, at an arms conference in Wiesbaden. Among the program's listed top priorities are uncrewed aerial systems, robot ground vehicles, missiles, and laser weapons. "Test in Ukraine" will require the contractor to teach Ukrainian troops how to use the prototype, though this can optionally be done online, Brave1 said in a statement. After that, Ukraine will assume control over how the tech is used on its frontline. "You hand over your product to Brave1, and we take care of the rest," the organization said on its website. Kyiv also hopes to pair the foreign arms makers with its own manufacturers to produce the tested weapons locally. Ukraine is already a testbed for many NATO weapons against Russian capabilities, from armored vehicles to long-range missiles to anti-tank munitions. But the announcement comes amid some concern in the greater arms industry that contractors may be developing new weapons after studying the Ukraine war, but aren't testing them in combat. "If you are a drone company and you do not have your kit on the frontline in Ukraine, you might as well give up," Luke Pollard, the UK's minister of state for the armed forces, said in May. One British defense executive, Justin Hedges, told Business Insider earlier this month that drones have to be tested daily in combat to avoid becoming obsolete. "If your system is not in day-to-day use on the frontline of Ukraine, it becomes very quickly out of date," Hedges told BI's Mia Jankowicz. Drone warfare has evolved drastically over the last three years of the war. First-person-view UAVs have come to dominate the battlefield, but electronic warfare is increasingly stifling their effectiveness. As a result, unjammable fiber-optic drones are now on the rise, forcing both sides to rely more on low-tech defensive measures such as 12-gauge shotguns to destroy drones kinetically and fishing nets to entangle them mid-flight. Last month, Ukraine debuted a new type of rifle bullet that can discharge fragment spreads at greater range to counter incoming FPV drones. Russian troops were producing their own DIY version months ago. Meanwhile, Ukraine is going all in on bolstering its defense manufacturing industry, offering its local weapons-making experience to Western countries while ramping up production of domestic arms. Its new testing initiative could also provide additional weapons supplies for its troops fighting against Russia's war of attrition, both in manpower and matériel. A spokesperson for Brave1 did not respond to a request for comment sent outside regular business hours. Russia's defense and foreign affairs ministries also did not respond to a similar request sent by BI.
Yahoo
19 minutes ago
- Yahoo
Buy NextEra Stock Down 20% for Value, Dividends, and AI Growth
NextEra Energy (NEE) stock tripled the S&P 500 over the past 25 years, soaring 1,140% as the renewable energy and Florida-based utility powerhouse steadily grew its earnings and raised its dividend. NEE trades 20% below its highs heading into Q2 earnings release on July 23. The energy stock underperformed over the last five years as Wall Street grew concerned about slowing earnings and dividend growth, as well as the possibility that some of the beneficial government subsidies for renewable energy would slowly disappear. On top of that, higher interest rates made dividend-paying utility stocks less attractive. Yet, NextEra Energy maintained its earnings guidance after its first quarter release and continues to expect to grow its dividends by 10% a year through at least 2026, off a 2024 base. Plus, the Fed is set to lower interest rates again in the back half of 2025, and the nuclear and renewable energy boom remains full steam ahead as the U.S. races to boost energy capacity. Now might be a great time for traders and long-term investors to buy beaten-down NextEra Energy stock down 20% from its peaks as it rides multiple converging megatrends such as the energy-hungry AI boom, electrification, and broader energy infrastructure expansion. Image Source: Zacks Investment Research Why NextEra Energy is a Top Long-Term Buy and Hold Stock NEE operates one of the largest electric utilities, Florida Power & Light Company, in the U.S. The company's ability to grow in a major economic hub is critical. On top of that, its subsidiary, NextEra Energy Resources, is one of the leading electric energy infrastructure companies in the world. NextEra Energy is one of the largest producers of wind and solar energy on the planet. It is also a battery storage leader, a natural gas compnay, and an under-the-radar nuclear energy standout. The company boasts 38 GW of generation and storage in operation and a 28 GW backlog. Image Source: Zacks Investment Research This backdrop makes NextEra Energy a long-term winner as tech companies such as Meta and Amazon turn to nuclear and renewables (and nat gas) to drive their AI growth. On top of that, the U.S. government is all on nuclear and beyond as the country attempts to slowly wean off fossil fuels while growing the economy and using more energy than ever before due to AI. NextEra Energy is projected to grow its adjusted earnings by 7% in 2025 and 8% next year, following a 10% average expansion in the past five years. Its earnings revisions are trending higher heading into its Q2 report, and it's topped our bottom-line estimates for five years running. NEE is projected to grow its revenue by 17% and 11%, respectively. Image Source: Zacks Investment Research The stock has climbed around 190% in the past decade, lagging not too far behind the S&P 500's 205% despite its massive underperformance over the last five years. NEE did crush its sector's 22% run during that period. It is up 4% in 2025 while trading 20% below its highs and 8% under its average Zacks price target. NextEra Energy is holding ground above its pre-Covid selloff highs. It's attempting to climb above its long-term 50-week and 200-week moving averages and its YTD highs, which could lead to a breakout. On the valuation front, NextEra Energy trades over 40% below its highs and near its 25-year median at 19.5X forward 12-month earnings. NEE trades at a solid discount to the benchmark's 22.6X and not too much of a premium to its industry despite its long-term outperformance (+475 in the past 15 years vs. 77%). Image Source: Zacks Investment Research The $155 billion market cap energy and utility powerhouse is the largest holding in the Utilities Select Sector SPDR ETF (XLU), showcasing its standing and stability in the space. NextEra's 3% dividend yield roughly matches its Utility - Electric Power industry, and it's one of roughly 70 S&P 500 Dividend Aristocrats (meaning it's paid and raised dividends for at least 25 straight years). Long-term investors have a chance to buy the next-generation energy and utility powerhouse at a solid discount. And traders can get in on NEE stock ahead of a potential post-earnings breakout if it impresses Wall Street. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Utilities Select Sector SPDR ETF (XLU): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Kinder Morgan kicks off oil and gas earnings season with a bullish outlook, in part thanks to thirsty data centers
While most of the nation's power focus is on servicing the rise of data centers and AI, the biggest driver of natural gas demand is exports and the rapid buildout of liquefied natural gas terminals to supply the world. Houston-based Kinder Morgan (No. 289 in the Fortune 500) is leading the charge with a handful of other developers to rapidly build the needed natural gas pipelines throughout the country to supply both the surging LNG and data center sectors and to avoid having pipelines create a bottleneck for growth. Kinder Morgan co-founder and executive chairman Rich Kinder kicked off earnings season for the oil and gas industry after market close July 16 with his bullishness on global gas demand, which is why the company has added about $6 billion in projects costs to its now-$9.3 billion project backlog in the past 12 months. The industry is focusing a lot on 'rapidly growing demand in America,' Kinder said. 'But as we all know, the gas market is international in nature, and a great deal of the growth potential for U.S. production is driven by that worldwide increase in demand.' He cited projections from Exxon Mobil and the U.S. Department of Energy—dating back to the Biden administration last year—that estimated global gas demand could easily surge by 25% or so from now until 2050, even as renewable energy growth keeps soaring, led by growing populations and wealth in Asia and Africa. Natural gas must be liquefied for export overseas, which has triggered the massive race to build out LNG facilities, especially along the Texas and Louisiana Gulf Coast. The U.S. is producing more gas than it can consume domestically because of the shale gas boom that kicked off 20 years ago. In fact, the U.S. used to be an LNG importer. 'It will be LNG which will satisfy the bulk of this additional demand, and I think it will grow faster than the overall demand for natural gas,' Kinder said in the earnings call. Rising supplies and demand The U.S. produced 103.5 billion cubic feet per day (Bcf/d) of gas on average in 2024, more than doubling U.S. natural gas volumes in 20 years. That's already on the rise in 2025, up to 107.2 Bcf/d for the month of April, according to the Energy Department. Although crude oil pricing and production volumes have stagnated, the gas side of the industry keeps growing. North America's LNG export capacity is on track to more than double between 2023 and 2028, from 11.4 Bcf/d in 2023 to 24.4 Bcf/d in 2028, according to the Energy Department, and continue growing well into the 2030s, eventually tripling capacity from the 2023 baseline. The U.S. has led the world in gas production for 15 years and, for just more than two years, now exports the most LNG, having surpassed Qatar. Kinder Morgan aims to move much of that gas from the shale fields to the LNG facilities and data centers. Already, Kinder Morgan helps move 40% of all the U.S. natural gas produced. 'When you add the international LNG growth to the robust need for gas to satisfy U.S. domestic power and industrial demand…it signals to me that the positive natural gas story has legs and will last for decades to come,' Kinder said. The company's new projects are about half-and-half focused on serving power demand growth or LNG expansions, said CEO Kim Dang. Kinder Morgan is primarily focused on building pipelines to feed data center growth from Arizona to South Carolina and beyond. The LNG growth is concentrated on Texas and Louisiana, as well as the company's Elba Island LNG facilities in Georgia. The newest expansion announced July 16 is to add to the planned Trident Intrastate Pipeline, which isn't even built yet. The expansion will add to the pipeline's capacity, growing from 1.5 Bcf/d to 2.0 Bcf/d as it stretches 216 miles from west of Houston to LNG hubs by the Texas-Louisiana border. Research firm RBN Energy recently called Trident a 'game changer for Gulf Coast LNG terminals' by solving the logistical challenge of getting gas through the congested Houston area by essentially taking a scenic route north of the nation's fourth-most-populous city. Kinder Morgan also is expanding the Gulf Coast Express Pipeline from the Permian Basin in West Texas to LNG facilities in South Texas, as well as the Evangeline Pass pipeline project in Louisiana to service LNG hubs there. Dang said Kinder Morgan's volumes feeding LNG facilities will growth 50% from now through 2028, up to 12 Bcf/d. Throughout the Deep South, the company has its Mississippi Crossing and South System Expansion 4 projects to move more gas into Mississippi, Alabama, Georgia, and South Carolina, including to potential data center projects that are on the rise in the South. This story was originally featured on